Pliant Therapeutics Q2 net loss $55.9M; cash $438.1M; bexotegrast trials on track

PLIANT THERAPEUTICS, INC.

2025-Q2 EPS reported -$1.71 vs consensus -$0.71 ▼ miss (-141.1%)

Net loss $55.9M vs $41.2M prior year; R&D expense up to $45.6M driven by BEACON-IPF trial.
Cash, equivalents & short-term investments $438.1M as of June 30, 2024.
Phase 2a PET imaging trial showed reduced total lung collagen and improved FVC in IPF patients on bexotegrast.
BEACON-IPF Phase 2b enrollment on track for Q1 2025 completion; data anticipated mid-2026.
Steve Krognes, former Denali Therapeutics CFO, appointed to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.